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Introduction
Spurred on by heavy antimicrobial use in healthcare systems
worldwide, antimicrobial resistance (AMR) is a preeminent global
health crisis. Antimicrobials are also economically important as
antimicrobial growth-promotants (AGPs) for food animals. Due to
connections between antimicrobial use in food animals and
increased AMR arising in zoonotic pathogens, many governments
worldwide have enacted or proposed legislation intended to curb
veterinary antimicrobial use. We reviewed this information to
propose possible implications of the recent AGP regulations in the
United States.
Observed Effects of EU Ban
Animal medicine and health:
• Apparent overall decreases in antimicrobial use per lb. biomass
• Increase in therapeutic use of food animal antimicrobials
• Noted decreases in some AMR prevalence
Human Health:
• Negligible effect on continually-increasing AMR prevalence,
with possible exception of vancomycin
Economic Impacts:
• Lower overall production in some countries (~1%) and increase
in domestic meat price (~1%)2
• Increase need to import in some countries
Figure 1. Flow of zoonotic AMR through animals, the environment, and humans3
Possible United States impacts
Animal medicine and health:
• Increased therapeutic use of livestock antimicrobials
• Increased use of antimicrobial alternatives (vaccination
programs, antimicrobial peptides, biosecurity measures, etc.)
• Increase in weanling pig mortality
• Decrease in some AMR prevalence
Human Health:
• Negligible effect on continually-increasing AMR prevalence
Economic Impacts:
• Protection against negative trade impacts caused by anti-AGP
food import markets
• Increase appeal to niche AGP free markets
• Slightly (~1-3%) increased prices of food animal products5
Recommendations
• Continue advancing science-based judicious antimicrobial usage
in both animals and humans
• Define comparisons between human and animal antimicrobial
doses
• Expand and standardize monitoring and surveillance
infrastructures for antimicrobial usage and resistance prevalence
in both humans and animals. Do not exclude companion animals
• Continue to invest in new antimicrobials and alternatives
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Year Regulation
1972–
1974
EU bans on tetracycline, penicillin, and streptomycin as 
AGPs
1986 Swedish ban on all AGPs
1995 Danish ban on avoparcin
1996 German ban on avoparcin use in food animals
1997 EU ban on food animal avoparcin use, Dutch ban on 
olaquindox and carbadox use in food animals
1998 Danish ban on virginiamycin use in food animals
1999 EU ban on olaquindox, carbadox, bacitracin, tylosin, 
spiramycin, and virginiamycin
2006 EU-wide ban on all AGPs
Table 1. Food animal antimicrobial regulations within the European Union1
FDA Guidances/Regulations4
FDA Guidances:
• non-binding statements of the FDA’s stance on an issue
Veterinary Feed Directive:
• A category of regulatory control created by the Animal Drug
Availability Act in 1996. For certain drugs that are used in animal
feeds, it requires veterinary approval before the sale of certain
drugs used in animal feed. Approval is not a prescription.
“medically important” antimicrobials were moved to this
designation on January 1, 2017, and had growth promotion uses
removed from their indication label. “Off-label” use is illegal.
2003 - Guidance 152:
• Outlines thee process to assess the risk of AMR from animal
antimicrobial use.
2012 - Guidance 209:
• Advocates for the requirement of VFD approval for human-use
“medically important” antimicrobials
2013 - Guidance 213:
• Describes the process for how drug manufacturers can remove
growth promotion claims from labels and how to add prevention
and therapeutic claims.
